Valentina Gigliucci

Valentina Gigliucci

Auto-generated profile, based on publicly available information

Valentina Gigliucci

CNR, Institute of Neuroscience, Milan, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Current Biology
Verified
Journal Article
Closed access
VFValentina Ferretti
Valentina Ferretti
FMFederica Maltese
Federica Maltese
GCGabriella Contarini
Gabriella Contarini
MNMarco Nigro
Marco Nigro
ABAlessandra Bonavia
Alessandra Bonavia
FPFrancesco Papaleo
Francesco Papaleo

2 March 2013 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
VGValentina Gigliucci
Valentina Gigliucci
GOGrainne O’dowd
Grainne O’dowd
SCSheena Casey
Sheena Casey
DEDanielle Egan
Danielle Egan
SGSinead Gibney
Sinead Gibney
AHAndrew Harkin
Andrew Harkin

25 April 2016 in Journal of Neuroendocrinology
Verified
Journal Article
Open access
PDF file
IPIlaria Passoni
Ilaria Passoni
MLMarianna Leonzino
Marianna Leonzino
VGValentina Gigliucci
Valentina Gigliucci
BCBice Chini
Bice Chini
MBMarta Busnelli
Marta Busnelli
Carbetocin, a long‐acting oxytocin analogue, has been reported to elicit interesting and peculiar behavioural effects. The present study investigated the molecular pharmacology of carbetocin, aiming to better understand the molecular basis of its action in the brain. Using bioluminescence resonance energy transfer biosensors, we characterised the effects of carbetocin on the three human oxytocin/vasopressin receptors expressed in the nervous system: the oxytocin receptor (OXTR) and the vasopressin V1a (V1aR) and V1b (V1bR) receptors. Our results indicate that (i) carbetocin activates theOXTRbut not the V1aR and V1bR at which it may act as an antagonist; (ii) carbetocin selectively activates only theOXTR/Gq pathway displaying a strong functional selectivity; (iii) carbetocin is a partial agonist at theOXTR/Gq coupling; (iv) carbetocin promotesOXTRinternalisation via a previously unreported β‐arrestin‐independent pathway; and (v) carbetocin does not induceOXTRrecycling to the plasma membrane. Altogether, these molecular pharmacology features identify carbetocin as a substantially different analogue compared to the endogenous oxytocin and, consequently, carbetocin is not expected to mimic oxytocin in the brain. Whether these unique features of carbetocin could be exploited therapeutically remains to be established.

5 November 2015 in Frontiers in Neuroscience
Verified
Journal Article
Open access
Maria Grazia MorgeseMaria Grazia Morgese
Maria Grazia Morgese
MCMarilena Colaianna
Marilena Colaianna
EMEmanuela Mhillaj
Emanuela Mhillaj
MZMargherita Zotti
Margherita Zotti
SSStefania Schiavone
Stefania Schiavone
LTLuigia Trabace
Luigia Trabace
Strong evidence showed neurotoxic properties of beta amyloid (Aβ) and its pivotal role in the Alzheimer’s disease (AD) pathogenesis. Beside, experimental data suggest that Aβ may have physiological roles considering that such soluble peptide is produced and secreted during normal cellular activity. There is now suggestive evidence that neurodegenerative conditions, like AD, involve nitric oxide (NO) in their pathogenesis. Nitric oxide also possess potent neuromodulatory actions in brain regions, such as prefrontal cortex (PFC), hippocampus (HIPP) and nucleus accumbens (NAC). In the present study, we evaluated the effect of acute Aβ injection on norepinephrine (NE) content before and after pharmacological manipulations of nitrergic system in above mentioned areas. Moreover, effects of the peptide on NOS activity were evaluated. Our data showed that 2 hours after i.c.v. soluble Aβ administration, NE concentrations were significantly increased in the considered areas along with increased iNOS activity. Pre-treatment with NOS inhibitors, 7-Nitroindazole (7-NI) and N6-(1-iminoethyl)-L-lysine-dihydrochloride (L-NIL), reversed Aβ-induced changes. Ultimately, pharmacological block of interleukin1 (IL-1) receptors prevented NE increase in all brain regions. Taken together our findings suggest that NO and IL-1 are critically involved in regional noradrenergic alterations induced by soluble Aβ injection.

1 February 2010 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Open access
VGValentina Gigliucci
Valentina Gigliucci
KBKathleen Niamh Buckley
Kathleen Niamh Buckley
JNJohn Nunan
John Nunan
KOKaren O'Shea
Karen O'Shea
AHAndrew Harkin
Andrew Harkin
The present study determined regional serotonin (5-HT) synthesis and metabolism changes associated with the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine (L-NA) and the influence of 5-HT receptor blockade in the antidepressant-like actions of L-NA in the forced swimming test (FST). Regional effects of L-NA (5,10 and 20mg/kg i.p.) on tryptophan hydroxylase (TPH) activity, the rate limiting enzyme for 5-HT synthesis, were determined by measuring accumulation of the transient intermediate 5-hydoxytryptophan (5-HTP) following in vivo administration of the amino acid decarboxylase inhibitor, NSD 1015 (100mg/kg). L-NA (5-20mg/kg) dose dependently increased 5-HTP accumulation, particularly in the amygdaloid cortex, following exposure to the FST. L-NA also provoked an increase in regional brain 5-HIAA concentrations and in the 5-HIAA:5-HT metabolism ratio. Co-treatment with NSD-1015 failed to consistently modify the antidepressant-like effects of L-NA in the FST. Sub-active doses of L-NA (1mg/kg) and the 5-HT re-uptake inhibitor fluoxetine (2.5mg/kg) acted synergistically to increase swimming in the test. Co-treatment with the non-selective 5-HT receptor antagonist metergoline (1, 2 and 4mg/kg), attenuated the L-NA (20mg/kg)-induced reduction in immobility and increase in swimming behaviours. Metergoline alone however provoked an increase in immobility and reduction in swimming behaviours in the test. A similar response was obtained following co-treatment with the preferential 5-HT(2A) receptor antagonist ketanserin (5mg/kg) and the 5-HT(2C) receptor antagonist RO-430440 (5mg/kg). Co-treatment with the 5-HT(1A) receptor antagonist WAY 100635 (0.3mg/kg) or the 5-HT(1B) receptor antagonist GR 127935 (4mg/kg) failed to influence the antidepressant-like activity of L-NA. Taken together these data provide further support for a role for 5-HT in the antidepressant-like properties of NOS inhibitors.

1 August 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
VGValentina Gigliucci
Valentina Gigliucci
SGShane Gormley
Shane Gormley
SGSinead Gibney
Sinead Gibney
JRJennifer Rouine
Jennifer Rouine
CKChristian Matthias Kerskens
Christian Matthias Kerskens
AHAndrew Harkin
Andrew Harkin